TENM1 and glioblastoma: Taking into consideration the functional studies, the in vivo models, and the regulatory pathways that modulate the expression of ODZ1, which are key pathways in the pathogenesis and/or development of GBM, there seems to be some good evidence to postulate ODZ1 as a potential therapeutic target.